Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study - Scorecard - MDSpire
Advertisement
Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study
Clinical Scorecard: Evaluating the Impact of Antiviral Therapy and Statin Administration on the Risk of Decompensated Cirrhosis in Hepatitis C Patients: A Time-Dependent Retrospective Cohort Study
At a Glance
Category
Detail
Condition
Hepatitis C Virus (HCV)
Key Mechanisms
Sustained virological response (SVR) and statin treatment associated with reduced risk of decompensated cirrhosis.
Target Population
Patients with chronic hepatitis C.
Care Setting
Retrospective cohort study using electronic medical records.
Key Highlights
SVR associated with aHR 0.17 for reduced risk of decompensated cirrhosis.
Statin use associated with aHR 0.68 for lower risk of decompensation.
Study included 16,275 patients with 1718 incidents of decompensated cirrhosis.
Guideline-Based Recommendations
Diagnosis
Confirm chronic HCV diagnosis via medical chart abstraction.
Management
Consider antiviral treatment and statin therapy to reduce risk of decompensation.
Monitoring & Follow-up
Monitor for signs of decompensated cirrhosis in patients with HCV.
Risks
Additional risk factors include BMI >25, male sex, and multiple comorbidities.
Patient & Prescribing Data
Patients with chronic hepatitis C.
Both SVR and statin treatment are associated with reduced risk of decompensation.
Clinical Best Practices
Utilize time-varying analysis for treatment status in chronic HCV patients.
Incorporate statin therapy in management plans for patients with HCV.
